Security key
19188J409
Cocrystal Pharma, Inc. - Common Stock, par value $0.001 per share (COCP)
CUSIP: 19188J409
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 776,191
- Total 13F value
- $783,754
- Share change
- +5,701
- SEC-reported price per share
- $1.01
- Number of holders
- 25
- Value change
- +$6,975
- Number of buys
- 8
- Number of sells
- 8
- Shares outstanding
- 13,831,528
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2026
Institutions
25
Top holders
10
COCP full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q4 2025
Cocrystal Pharma, Inc. SEC filings
Cocrystal Pharma, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 19188J409
Recent filing periods:
Ownership snapshot
Top reported holders of COCP - Cocrystal Pharma, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Et al Phillip Frost MD
Disclosed value leader
Et al Phillip Frost MD
Comparable rows
15/15
Latest evidence
31 Dec 2025
13D/G
3/4/5
13F
Lead comparable stake: 18%
13D/G row: Et al Phillip Frost MD
Showing 1-6 of 15 holder rows.
Quick read
Et al Phillip Frost MD leads the comparable SEC ownership view at 18%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Et al Phillip Frost MD's linked filing trail.
Comparable ownership
Top 5
Et al Phillip Frost MD
18%
VANGUARD GROUP INC
1.9%
RENAISSANCE TECHNOLOGIES LLC
0.91%
GEODE CAPITAL MANAGEMENT, LLC
0.6%
BlackRock, Inc.
0.53%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Et al Phillip Frost MD |
13D/G
3/4/5
Phillip Frost, M.D. · Director, 10%+ Owner
|
18%
|
$3,078,992
2,462,012 shares
|
+$1,349,571 | 28 Oct 2025 |
| VANGUARD GROUP INC |
13F
Company
|
1.9%
|
$258,444
263,987 shares
|
— | 31 Dec 2025 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
0.91%
|
$123,382
126,028 shares
|
— | 31 Dec 2025 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
0.6%
|
$80,778
82,499 shares
|
— | 31 Dec 2025 |
| BlackRock, Inc. |
13F
Company
|
0.53%
|
$72,197
73,746 shares
|
— | 31 Dec 2025 |
| T3 Companies, LLC |
13F
Company
|
0.38%
|
$51,202
52,300 shares
|
— | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
25
Shares
776,191
Rows available
25
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
26
Q1 2026 holders
25
Holder diff
-1
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 value | Q1 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend